These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 171670)

  • 1. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.
    Lamensans A; Chedid L; Lederer E; Rosselet JP; Gustafson RH; Spencer HJ; Ludwig B; Berger FM
    Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3656-60. PubMed ID: 171670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of delipidated mycobacterial cells and purified cell walls against Ehrlich carcinoma and a syngeneic lymphoid leukemia in mice.
    Chedid L; Lamensans A; Parant F; Parant M; Adam A; Petit JF; Lederer E
    Cancer Res; 1973 Sep; 33(9):2187-95. PubMed ID: 4725375
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy of experimental cancer by intralesional injection of emulsified nonliving mycobacteria: comparison of Mycobacterium bovis (BCG), Mycobacterium phlei, and Mycobacterium smegmatis.
    Yarkoni E; Rapp HJ
    Infect Immun; 1980 Jun; 28(3):887-92. PubMed ID: 6995326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R; Kodera Y; Ogura M; Yamada H
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
    Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
    Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic antitumor activity of Bacillus Calmette Guerin and purified protein derivatives against tumors in mice having tuberculin allergy.
    Abe S; Saito M; Yamazaki M; Mizuno D; Tsumita T
    Jpn J Exp Med; 1978 Oct; 48(5):455-7. PubMed ID: 372638
    [No Abstract]   [Full Text] [Related]  

  • 8. BCG inhibition of murine leudemia: local suppression and systemic tumor immunity require different doses.
    Bartlett GL; Purnell DM; Kreider JW
    Science; 1976 Jan; 191(4224):299-301. PubMed ID: 1108198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.
    Juy D; Chedid L
    Proc Natl Acad Sci U S A; 1975 Oct; 72(10):4105-9. PubMed ID: 812088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
    Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs.
    Fidler IJ; Kataoka T; Hanna MG
    Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological study of a nontoxic, water-soluble immunoadjuvant from mycobacterial cell walls.
    Chedid L; Parant M; Parant F; Gustafson RH; Berger FM
    Proc Natl Acad Sci U S A; 1972 Apr; 69(4):855-8. PubMed ID: 4337242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 15. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight water-soluble peptidoglycans as adjuvants and immunostimulants.
    Jollès P; Migliore-Samour D; Maral R; Floc'h F; Werner GH
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(2-4):331-40. PubMed ID: 241167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin, Mycobacterium bovis, as an immunomodulator in atopic diseases.
    Barlan I; Bahceciler NN; Akdis M; Akdis CA
    Immunol Allergy Clin North Am; 2006 May; 26(2):365-77, ix. PubMed ID: 16701150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cytokinetic analysis of bacillus calmette-guérin-induced growth control of a murine leukemia.
    Olsson L; Mathé G
    Cancer Res; 1977 Jun; 37(6):1743-9. PubMed ID: 322860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant protection against bacterial infection in granulocytopenic mice.
    Buhles WC; Shifrine M
    J Infect Dis; 1977 Jul; 136(1):90-5. PubMed ID: 328788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.